14-day Premium Trial Subscription Try For FreeTry Free
$1.37
+0.0700 (+5.38%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.22 $1.62 Friday, 3rd May 2024 AKBA stock ended at $1.37. This is 5.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 7.58% from a day low at $1.32 to a day high of $1.42.
90 days $1.22 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Dec 08, 2022 $0.309 $0.310 $0.293 $0.300 1 786 806
Dec 07, 2022 $0.293 $0.308 $0.281 $0.300 2 899 800
Dec 06, 2022 $0.290 $0.295 $0.281 $0.285 2 378 911
Dec 05, 2022 $0.281 $0.300 $0.281 $0.292 2 185 177
Dec 02, 2022 $0.297 $0.300 $0.279 $0.290 1 852 802
Dec 01, 2022 $0.270 $0.295 $0.266 $0.292 1 297 111
Nov 30, 2022 $0.250 $0.280 $0.250 $0.271 2 298 848
Nov 29, 2022 $0.255 $0.259 $0.243 $0.250 996 311
Nov 28, 2022 $0.260 $0.260 $0.250 $0.251 947 177
Nov 25, 2022 $0.259 $0.265 $0.253 $0.256 773 178
Nov 23, 2022 $0.260 $0.267 $0.253 $0.261 720 317
Nov 22, 2022 $0.260 $0.270 $0.252 $0.260 1 341 211
Nov 21, 2022 $0.258 $0.265 $0.250 $0.255 884 142
Nov 18, 2022 $0.251 $0.264 $0.246 $0.254 985 453
Nov 17, 2022 $0.257 $0.269 $0.243 $0.265 2 472 249
Nov 16, 2022 $0.270 $0.270 $0.251 $0.254 883 641
Nov 15, 2022 $0.262 $0.275 $0.252 $0.259 1 273 967
Nov 14, 2022 $0.280 $0.280 $0.255 $0.261 1 349 849
Nov 11, 2022 $0.280 $0.288 $0.260 $0.270 1 095 829
Nov 10, 2022 $0.250 $0.275 $0.250 $0.274 944 459
Nov 09, 2022 $0.260 $0.267 $0.253 $0.253 759 703
Nov 08, 2022 $0.285 $0.285 $0.260 $0.273 755 038
Nov 07, 2022 $0.270 $0.288 $0.252 $0.287 826 072
Nov 04, 2022 $0.260 $0.280 $0.257 $0.271 1 652 655
Nov 03, 2022 $0.256 $0.320 $0.256 $0.285 3 007 485
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT